Factors Associated with 24-Hour Mortality in Patients with Pneumonia at Emergency Department, Yasothon Hospital
Article Sidebar
Main Article Content
Abstract
Community-acquired pneumonia (CAP) is caused by an out-of-hospital microbial infection. Patients
usually present with signs and symptoms suggestive of a lower respiratory tract infection with abnormal
findings in chest radiograph occurring acutely or up to 2 weeks. Complications and mortality within the first
24 hours of CAP patients are critical. This study aimed to determine the characteristics, causes and factors
associated with 24-hour mortality of patient with pneumonia at emergency department of Yasothon
hospital. Study style is retrospective analytical study. The population group is the medical records of all
CAP patients in emergency department from October 1, 2020 to September 30, 2021. Early deaths, defined as death due to any cause within 24 hours after admission, were compared with all patients who survived
more than 24 hours after admission. In addition, early death and late death were compared. (patients who
died > 24 hours) and survivors.
Results: Of the 519 patients, the mortality rate within 24 hours after admission was 37 (7.1%) and after 24
hours was 92 (17.7%). Overall mortality rate was 129 (24.9%). The leading causes of death within 24 hours
were acute respiratory failure and septic shock with multiple organ failure. Independent factors associated
with early mortality were age 60 and over, altered mental status, multilobar infiltration, septic shock, severe
pneumonia and inappropriate antibiotic therapy.
Conclusion: Causes and factors associated with mortality within 24 hours of pneumonia patients admitted
to the Accident and Emergency Department, Yasothon Hospital include elderly patients, patients with
altered mental status, multilobar infiltration, septic shock, severe pneumonia and inappropriate antibiotic
therapy primarily caused by lack of protection against Burkholderia pseudomallei is also a risk factor.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของยโสธรเวชสาร
References
Udompanit W. Guidelines for the treatment
of community pneumonia in Thailand (For
adults). Bangkok: The Uravej Association of
Thailand; 2011.
Kaewnok W. Pneumonia. Weekly
Epidemiological Surveillance Report 2012;
: 90-8.
Welte T. Risk factors and severity scores in
hospitalized patients with communityacquired pneumonia: prediction of severity
and mortality. Eur J Clin Microbiol Infect Dis
; 31(1): 33–47. doi: 10.1007/s10096-011-
-4. PubMed PMID: 21533875.
Mandell LA, Bartlett JG, Dowell SF, File TM
Jr, Musher DM, Whitney C, et al. Update of
practice guidelines for the management of
community-acquired pneumonia in
immunocompetent adults. Clin Infect Dis
; 37(11): 1405–33. doi: 10.1086/380488.
PubMed PMID: 14614663.
Lode HM. Managing community-acquired
pneumonia: a European perspective. Respir
Med 2007; 101(9): 1864–73. doi: 10.1016/j.rmed.2007.04.008. PubMed PMID:
Lim WS, Baudouin SV, George RC, Hill AT,
Jamieson C, Le Jeune I, et al. BTS guidelines
for the management of community acquired
pneumonia in adults: update 2009. Thorax
; 64 Suppl 3: 1-55. doi:
1136/thx.2009.121434. PubMed PMID:
Mandell LA, Wunderink RG, Anzueto A,
Bartlett JG, Campbell GD, Dean NC, et al.
Infectious Diseases Society of
America/American Thoracic Society
consensus guidelines on the management of
community-acquired pneumonia in adults.
Clin Infect Dis 2007; 44 Suppl 2 (Suppl 2):
S27-72. doi: 10.1086/511159. PubMed PMID:
Ebell MH. Outpatient vs. inpatient treatment
of community acquired pneumonia. Fam
Pract Manag 2006; 13(4): 41-4. PubMed PMID:
Community-acquired pneumonia in adults in
British hospitals in 1982-1983: a survey of
aetiology, mortality, prognostic factors and
outcome. The British Thoracic Society and
the Public Health Laboratory Service. Q J
Med 1987; 62(239):195-220. PubMed PMID:
Lim WS, van der Eerden MM, Laing R,
Boersma WG, Karalus N, Town GI, et al.
Defining community acquired pneumonia
severity on presentation to hospital: an
international derivation and validation study.
Thorax 2003; 58(5): 377-82. doi:
1136/thorax.58.5.377. PubMed PMID:
Minogue MF, Coley CM, Fine MJ, Marrie TJ,
Kapoor WN, Singer DE. Patients hospitalized
after initial outpatient treatment for
community-acquired pneumonia. Ann Emerg
Med 1998; 31(3): 376-80. doi: 10.1016/s0196-
(98)70350-6. PubMed PMID: 9506497.
Schnoor M, Klante T, Beckmann M, Robra
BP, Welte T, Raspe H, et al. Risk factors for
community-acquired pneumonia in German
adults: the impact of children in the
household. Epidemiol Infect 2007; 135(8):
–97. doi: 10.1017/S0950268807007832.
PubMed PMID: 17291378.
Mandell LA, Marrie TJ, Grossman RF, Chow
AW, Hyland RH. Canadian guidelines for the
initial management of community-acquired
pneumonia: an evidence-based update by
the Canadian Infectious Diseases Society and
the Canadian Thoracic Society. The Canadian
Community-Acquired Pneumonia Working
Group. Clin Infect Dis 2000; 31(2): 383–421.
doi: 10.1086/313959. PubMed PMID:
British Thoracic Society Standards of Care
Committee. BTS Guidelines for the
Management of Community Acquired
Pneumonia in Adults. Thorax 2001; 56 Suppl
(Suppl 4): IV1–64. doi:
1136/thorax.56.suppl_4.iv1. PubMed
PMID: 11713364.
Rosón B, Carratalà J, Fernández-Sabé N,
Tubau F, Manresa F, Gudiol F. Causes and
factors associated with early failure in
hospitalized patients with communityacquired pneumonia. Arch Intern Med 2004;
(5): 502–8. doi:
1001/archinte.164.5.502. PubMed PMID:
Rosón B, Carratalà J, Dorca J, Casanova A,
Manresa F, Gudiol F. Etiology, reasons for
hospitalization, risk classes and outcomes of
patients with community-acquired
pneumonia hospitalized on the basis of
conventional admission criteria. Clin Infect
Dis 2001; 33(2): 158–65. doi: 10.1086/321808.
PubMed PMID: 11418874. 17. Pallares R, Liñares J, Vadillo M, Cabellos C,
Manresa F, Viladrich PF, et al. Resistance to
penicillin and cephalosporin and mortality
from severe pneumococcal pneumonia in
Barcelona, Spain. N Engl J Med 1995; 333(8):
–80. doi:
1056/NEJM199508243330802. PubMed
PMID: 7623879.
Yu VL, Chiou CC, Feldman C, Ortqvist A,
Rello J, Morris AJ, et al. An international
prospective study of pneumococcal
bacteremia: correlation with in vitro
resistance, antibiotics administered, and
clinical outcome. Clin Infect Dis 2003; 37(2):
–7. doi: 10.1086/377534. PubMed PMID:
Confalonieri M, Urbino R, Potena A, Piattella
M, Parigi P, Puccio G, et al. Hydrocortisone
infusion for severe community-acquired
pneumonia: a preliminary randomized study.
Am J Respir Crit Care Med 2005; 171(3): 242–
doi: 10.1164/rccm.200406-808OC. PubMed
PMID: 15557131.
Garcia-Vidal C, Calbo E, Pascual V, Ferrer C,
Quintana S, Garau J. Effects of systemic
steroids in patients with severe communityacquired pneumonia. Eur Respir J 2007;
(5): 951–6. doi:
1183/09031936.00027607. PubMed PMID:
Fisman DN, Abrutyn E, Spaude KA, Kim A,
Kirchner C, Daley J. Prior pneumococcal
vaccination is associated with reduced
death, complications, and length of stay
among hospitalized adults with communityacquired pneumonia. Clin Infect Dis 2006;
(8): 1093–101. doi: 10.1086/501354.
PubMed PMID: 16575726.
Vila-Córcoles A, Ochoa-Gondar O, Llor C,
Hospital I, Rodríguez T, Gómez A. Protective
effect of pneumococcal vaccine against
death by pneumonia in elderly subjects. Eur
Respir J 2005; 26(6): 1086–91. doi:
1183/09031936.05.00030205. PubMed
PMID: 16319340.
Greci LS, Katz DL, Jekel J. Vaccinations in
pneumonia (VIP): pneumococcal and
influenza vaccination patterns among
patients hospitalized for pneumonia. Prev
Med 2005; 40(4): 384–8. doi:
1016/j.ypmed.2004.06.024. PubMed PMID:
Musher DM, Alexandraki I, Graviss EA,
Yanbeiy N, Eid A, Inderias LA, et al.
Bacteremic and nonbacteremic
pneumococcal pneumonia. A prospective
study. Medicine (Baltimore) 2000; 79(4): 210–
doi: 10.1097/00005792-200007000-00002.
PubMed PMID: 10941350.
Fine MJ, Auble TE, Yealy DM, Hanusa BH,
Weissfeld LA, Singer DE, et al. A prediction
rule to identify low-risk patients with
community-acquired pneumonia. N Engl J
Med 1997; 336(4): 243–50. doi:
1056/NEJM199701233360402. PubMed
PMID: 8995086.
Fine MJ, Smith MA, Carson CA, Mutha SS,
Sankey SS, Weissfeld LA, et al. Prognosis and
outcomes of patients with communityacquired pneumonia. A meta-analysis. JAMA
; 275(2): 134–41. PubMed PMID:
Mortensen EM, Coley CM, Singer DE, Marrie
TJ, Obrosky DS, Kapoor WN, et al. Causes of
death for patients with community-acquired
pneumonia: results from the Pneumonia
Patient Outcomes Research Team Cohort
Study. Arch Intern Med 2002; 162(9): 1059–
doi: 10.1001/archinte.162.9.1059.
PubMed PMID: 11996618